Drug Database · Clinicians

Mosapride

Brands (4) Gasmotin, Gastiin CR, Gastorid…Show all

Gastroprokinetic; Drug for functional gastrointestinal el disorders (propulsive); and others PH FDA category

Rx · Prescription drug4 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Contraindications

  • None listed in the retrieved insert
renalcarematters.com, reviewed

Dosing: Adult

  • Gastrointestinal symptoms of chronic gastritis: 15 mg/day in 3 divided doses; reassess at about 2 weeks; older adults may need 7.5 mg/day
  • Adjunct to bowel preparation before barium enema: 20 mg at the start of the lavage solution and 20 mg after it is finished
renalcarematters.com, reviewed

Dosing: Altered kidney function

Mosapride is a serotonin 5-HT4 agonist prokinetic metabolized by CYP3A4; only 0.1% of a dose is excreted unchanged in urine. The Japanese insert does not address kidney impairment but advises caution and dose reduction (for example 7.5 mg/day) in older adults, and warns of fulminant hepatitis. It has no US FDA label.

Kidney function measure: The Japanese insert does not address kidney impairment; bands shown on creatinine clearance (CrCl).

Show full dosing details
CrCl ≥60 mL/min
Chronic gastritis symptoms: 15 mg/day in 3 divided doses before or after meals; reassess after about 2 weeks (PMDA insert).
CrCl 30–59 mL/min
Mostly hepatic (0.1% unchanged in urine); the Japanese insert gives no kidney dosing and there are no CKD data. Consider 7.5 mg/day if adverse effects occur, as for older adults (insert 9.8).
CrCl 15–29 mL/min
Mostly hepatic (0.1% unchanged in urine); the Japanese insert gives no kidney dosing and there are no CKD data. Consider 7.5 mg/day if adverse effects occur, as for older adults (insert 9.8).
CrCl <15 mL/min (not on dialysis)
Mostly hepatic (0.1% unchanged in urine); the Japanese insert gives no kidney dosing and there are no CKD data. Consider 7.5 mg/day if adverse effects occur, as for older adults (insert 9.8).
Hemodialysis (intermittent)
Not studied in dialysis; no dose given.
Peritoneal dialysis
Not studied in dialysis; no dose given.
CRRT
Not studied in dialysis; no dose given.
  • Dialyzable? Not stated (99% protein-bound).
  • Monitoring Liver function: fulminant hepatitis and severe liver dysfunction reported (some fatal); avoid prolonged use without reassessment; stop for fatigue, anorexia, dark urine or jaundice (PMDA insert).
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: PMDA (Japan) product information (October 2023). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
No pediatric trials (PMDA insert).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 5 mg
  • Controlled-release tablet: 15 mg

Registered products in the Philippines

4 products registered with the Food and Drug Administration (FDA) Philippines list Mosapride as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products4
Philippine FDA-registered products for Mosapride
Package insert
GasmotinMosapride citrate (as dihydrate)
5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's with aluminum wrapping (Box of 30's)
Rx
Interthai Pharmaceutical Manufacturing Ltd.Thailand
Zuellig Pharma CorporationImporter: Hi-Eisai Pharmaceutical Inc.
DR-XY35905
Jul 30, 2030
Gastiin CRMosapride citrate (as dihydrate)
15 mg Controlled Release TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Korea United Pharm. Inc.Korea
United Douglas Pharm. Philippines, Inc.
DR-XY 48036
May 25, 2027
GastoridMosapride Citrate
5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Aju Pharm Co., Ltd.Republic of Korea
Kaufmann Pharma Inc.Importer: Ambica International Corporation
DRP-6554-01
Apr 27, 2037
GutmovinMosapride Citrate
5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Aju Pharm Co., Ltd.Republic of Korea
Justright Healthcare Inc.Importer: Ambica International Corporation
DRP-6554
Mar 4, 2038

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Anticholinergics (atropine, butylscopolamine)MinorReduced prokinetic effect.Separate doses.
Erythromycin and other CYP3A4 inhibitorsMinorErythromycin raised mosapride Cmax about 1.6-fold (42.1 to 65.7 ng/mL) and half-life from 1.6 to 2.4 hours (insert 16.7.1).Monitor.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Serious

  • Fulminant hepatitis, severe liver dysfunction, jaundice (some fatal)
renalcarematters.com, reviewed

Monitoring parameters

  • Liver function: fulminant hepatitis and severe liver dysfunction reported (some fatal); avoid prolonged use without reassessment; stop for fatigue, anorexia, dark urine or jaundice (PMDA insert). Kidney
  • Liver function and symptoms of hepatitis
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Time to peak0.8 hour
Half-life2.0 hours
Protein binding99.0%
Metabolism (CYP, transporters)Hepatic, mainly CYP3A4
Renal excretion kidney0.1% unchanged and 7.0% as main metabolite in urine (48 hours)
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Pharmaceuticals and Medical Devices Agency (Japan). Mosapride citrate tablets "NP" package insert [PMDA (Japan) product information, October 2023; no US FDA label]. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987190665102
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Nipro Corporation. (2023). Mosapride citrate tablets 2.5 mg and 5 mg "NP" [Japanese package insert, 1st edition, revised October 2023]. Pharmaceuticals and Medical Devices Agency (PMDA), Japan. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987190665102

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .